Weekly Recap: Sparsentan patent allowance and CEO succession
Travere Therapeutics, Inc. (NASDAQ:TVTX) won a USPTO Notice of Allowance for sparsentan methods and plans to seek issuance and FDA Orange Book listing while management shifts as CEO Eric Dube steps down Dec. 1, 2026 for an advisory role and Bradley L. Campbell takes the helm amid positive trader se…